| Name | Title | Contact Details |
|---|
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
Quintiles helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.”
Roswell Biotechnologies is a molecular electronics company transforming DNA sequencing with their latest platform, designed to deliver the disruptive performance required for future biomedical and industrial applications.